Epcoritamab (Epkinly)

Key Messages

• We recommend that Epkinly be reimbursed by public drug plans for the treatment of adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma grade 3B after 2 or more lines of systemic therapy and who have previously received or are unable to receive chimeric antigen receptor (CAR) T-cell therapy for a time-limited period while additional evidence is generated if certain conditions are met.
• Epkinly should only be covered to treat adults who have DLBCL, not otherwise specified, DLBCL transformed from indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma grade 3B that has come back or that did not respond to 2 or more previous treatments for their cancer, and who have also previously received CAR T-cell therapy, declined CAR T-cell therapy, or cannot receive CAR T-cell therapy.
• Epkinly should only be reimbursed if not given in combination with other anticancer drugs. Reimbursement of Epkinly should be discontinued if a patient’s cancer grows or spreads or if the treatment is unacceptably toxic to the patient. Epkinly should only be reimbursed when prescribed by specialists with experience managing large B-cell lymphoma (LBCL), and if its cost is reduced.